Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.